Annals of Oncology Podcasts

Genome instability and success of checkpoint inhibitors

Dr Sarah Derks, of Amsterdam UMC, discusses her recent editorial in Annals of Oncology on the report of Shitara et al. who presented an exploratory analysis from the KEYNOTE-061 trial evaluating the association of tTMB with PD-L1 and MSI-H and their relationship with clinical outcomes in patients with advanced gastric/GEJ cancer receiving second-line pembrolizumab or paclitaxel.

^{Derks S. Genome instability and success of checkpoint inhibitors: form and levels matter. Ann Oncol 2021; 32: 1073-1074.
Shitara K et al. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Ann Oncol 2021; 32: 1127-1136.}

Published in September 2021

Immunotherapy trials for metastatic triple-negative breast cancer

Dr Marleen Kok, of the Netherlands Cancer Institute, discusses her recent editorial, written with Dr Leonie Voorwerk, on the results of the IMpassion130 and IMpassion131 trials of immunotherapy in unresectable, locally advanced, or metastatic triple-negative breast cancer, results of which are both published in the August issue of Annals of Oncology.

Published in September 2021

IgE blockade in the management of eosinophil-associated recalcitrant pruritus

Professor Ralf Gutzmer, of the Skin Cancer Center Minden, discusss his recent editorial, with colleagues, on a the recently published study of Barrios et al, which sought to evaluate the efficacy and safety of IgE blockade with omalizumab in cancer patients with refractory pruritus-associated cutaneous adverse events related to checkpoint inhibitors and anti-HER2 agents.

^{Gutzmer R, Sibaud V, Hassel JC. IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy. Ann Oncol 2021; 32: 696-697.
Barrios DM, Phillips GS, Geisler AN et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol 2021; 32: 736-745.}

Published in July 2021

Cabazitaxel vs abiraterone or enzalutamide in poor prognosis metastatic CRPC

Professor Ronald de Wit, of the Erasmus MC Cancer Institute, Rotterdam, discusses the editorial he wrote with colleagues on the recent publication of Annala et al.They reported on a randomised, phase II study evaluating cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer.

^{Annala M, Fu S, Bacon JVW et al. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol 2021; 32: 896-905.
Robbrecht DHJ, Buck SAJ, de Wit R. Outcomes of treatment choices in poor prognosis prostate cancer: notagainst all odds. Ann Oncol 2021; 32: 831-832.}

Published in July 2021